Trial finds heart drug combination cuts kidney damage during septic shock surgery

A major randomized clinical trial has found that a simple adjustment to the drugs given during surgery for septic shock can significantly reduce the risk of acute kidney injury. The study, a collaboration between scientists at the University of Southampton and Zhejiang University School of Medicine in China, was published in the Journal of the American Medical Association. It tested whether adding dobutamine, a heart medication that improves blood flow, to the standard blood pressure drug norepinephrine during surgery could protect the kidneys of vulnerable patients. According to the trial data, patients who received the combination developed new or worsening kidney injuries far less often than those who received norepinephrine alone.

The trial enrolled 584 adult patients undergoing surgery across 39 hospitals in China. Half of the participants received an intraoperative infusion of dobutamine alongside norepinephrine, while the other half received norepinephrine alone, reflecting current standard care. The researchers tracked kidney function in the days following the operation. Fewer than a quarter of the patients given the drug combination developed new or worsening kidney injuries within a week after surgery, compared with around 35 per cent of those in the standard care group.

Septic shock has a global death rate as high as 50 per cent and is often triggered by an extreme immune response to an infection. Although emergency surgery usually clears the underlying infection, inflammation and surgical trauma can cause kidney injury among patients. Protecting these organs during the critical window of the operation has therefore been a long-standing challenge for the medical teams who care for them.

The problem, as the researchers explain, lies partly in the drugs conventionally used during these operations. Dr Nazrul Islam from the University of Southampton, a senior co-corresponding author of the study, said that standard medical care during septic shock surgery is to use blood pressure drugs that can accidentally starve the kidneys of vital blood. He added that the trial discovered that adding these two heart medications during the operation safely boosts blood flow, and that it also significantly cuts the risk of severe kidney damage, offering a safer way to protect vulnerable patients during high-risk surgery.

The benefits extended beyond simply reducing the number of kidney injuries. Dr Lihua Chu from Zhejiang University School of Medicine said the therapy was most effective at preventing serious forms of kidney injury, with moderate to severe kidney injuries roughly halved among patients receiving the combined drugs. She noted that patients taking the drug combination produced more urine right away and showed milder overall signs of organ strain during their first day in intensive care.

The treatment was not without side effects. The combination of dobutamine and norepinephrine triggered more frequent bouts of temporary elevated heart rate, known as tachycardia, affecting 41 per cent of patients compared with about 30 per cent in the group receiving norepinephrine alone. However, the researchers found no increase in serious complications, such as cardiac arrest or arrhythmias.

The findings arrive at a moment when the field has lacked clear guidance on this approach. Dr Xiangming Fang from Zhejiang University School of Medicine, the primary corresponding author of the study, said the research is timely because the International Guidelines for Management of Sepsis and Septic Shock recently said there was insufficient data to make a recommendation for the use of dobutamine. He said this can now clearly be changed, and that the team hopes the findings will help doctors rethink how they care for patients during high-risk emergency surgery.

The study’s design strengthens confidence in the result. As a randomized controlled clinical trial, it assigned patients to receive either the drug combination or standard care by chance, minimizing the possibility that differences in kidney outcomes were caused by underlying differences between the patient groups. The subject of research was people, meaning the findings relate directly to human patients rather than to animal or laboratory models. The full study is available through the Journal of the American Medical Association under DOI 10.1001/jama.2026.21322.

For clinicians, the practical appeal of the finding is its simplicity. According to the researchers, this straightforward adjustment could prevent thousands of patients from suffering kidney damage after surgery for septic shock. For a condition whose global death rate can reach as high as 50 per cent, a change to the drug regimen at the operating table may prove to be a meaningful advance in the surgical management of septic shock.

Subject of Research: Intraoperative dobutamine plus norepinephrine to prevent acute kidney injury in septic shock surgery

Article Title: Heart drug combo reduces kidney damage in septic shock surgery, major trial finds

Article References: Heart drug combo reduces kidney damage in septic shock surgery, major trial finds. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: septic shock, acute kidney injury, dobutamine, norepinephrine, randomized controlled trial, emergency surgery, JAMA, kidney protection, tachycardia, sepsis guidelines, University of Southampton, Zhejiang University